Seminars in Oncology
Volume 33 , Pages 18-24 , December 2006

New and Emerging Intraperitoneal (IP) Drugs for Ovarian Cancer Treatment

  • Franco M. Muggia

      Affiliations

    • Dr. Muggia has received grant or research support from and serves on the speakers bureau for Ortho Biotech Products, L.P. He is also a member of the Bristol-Myers Squibb Company advisory committee.
    • Corresponding Author InformationAddress reprint requests to Franco M. Muggia, MD, New York University Cancer Institute, 462 First Avenue C & D, Building 226, New York, NY 10016-9196.

References 

  1. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–1955
  2. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–1007
  3. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43
  4. National Cancer Institute Clinical Announcement. Intraperitoneal Chemotherapy of Ovarian Cancer. Available at: http://ctep.cancer.gov/highlights/clin_annc_010506.pdf (accessed November 1, 2006)
  5. Markman M. Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer. Comm Onc. 2006;3:352–353
  6. Ozols RF. Systemic therapy for ovarian cancer: Current status and new treatments. Semin Oncol. 2006;33(suppl 6):S3–S11
  7. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2006;100:27–32
  8. Ozols RF, Bookman MA, Du Bois A, et al. Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol. 2006;103:1–6
  9. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654–2666
  10. Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 2002;41:418–424
  11. Spriggs DR, Brady M, Rubin S, et al. A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG 162). Proc Am Soc Clin Oncol. 2004;22:499;(abstr)
  12. Canetta R, Bragman K, Smaldone L, et al. Carboplatin: Current status and future prospects. Cancer Treat Rev. 1988;15:17–32
  13. Colombo N, Speyer JL, Green M, et al. Phase II study of carboplatin in recurrent ovarian cancer: Severe hematologic toxicity in previously treated patients. Cancer Chemother Pharmacol. 1989;23:323–328
  14. Ozols RF, Behrens BC, Ostchega Y, et al. High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat Rev. 1985;12:59–65
  15. Wiltshaw E. Ovarian trials at the Royal Marsden. Cancer Treat Rev. 1985;12:67–71
  16. Speyer JL, Beller U, Colombo N, et al. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol. 1990;8:1335–1341
  17. Speyer JL, Sorich J. Intraperitoneal carboplatin: rationale and experience. Semin Oncol. 1992;19:107–113
  18. Miyagi Y, Fujiwara K, Kigawa J, et al. Development of a mathematical model of intraperitoneally intravenous infusion of carboplatin - A Sankai Gynecology Study Group study. Proc Am Soc Clin Oncol. 2004;22:547;(abstr 2037)
  19. Muggia FM, Groshen S, Russell C, et al. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: Analysis of results by prior sensitivity to platinum-based regimens. Gynecol Oncol. 1993;50:232–238
  20. Fujiwara K, Suzuki S, Ishikawa H, et al. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. Int J Gynecol Oncol. 2005;3:426–431
  21. Los G, Verdegaal EM, Mutsaers PH, et al. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159–165
  22. Markman M, Reichman B, Hakes T, et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol. 1993;50:100–104
  23. Bookman MA, McGuire WP, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol. 1996;14:1895–1902
  24. Krasner CN, Seiden MV, Fuller AF, et al. Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. J Clin Oncol. 2006;24:257s;(abstr 5008)
  25. McGuire WP, Markman M. Primary ovarian cancer chemotherapy: Current standards of care. Br J Cancer. 2003;89:S3–S8(suppl 3)
  26. de Bree E, Rosing H, Beijnen JH, et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs. 2003;14:103–110
  27. Francis P, Rowinsky E, Schneider J, et al. Phase I feasibility and pharmacologic study of weekly paclitaxel: A Gynecologic Oncology Group pilot study. J Clin Oncol. 1995;13:2961–2967
  28. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group study. J Clin Oncol. 1992;10:1485–1491
  29. Zanotti KM, Belinson JL, Kennedy AW, et al. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol. 2000;79:211–215
  30. Francis P, Schneider J, Hana L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol. 1994;12:2301–2308
  31. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96:1682–1691
  32. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. J Clin Oncol. 1990;8:1263–1268
  33. Ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665–685
  34. Kloover JS, Den Bakker MA, Gelderblom H, et al. Fatal outcome of a hypersensitivity reaction to paclitaxel: A critical review of premedication regimens. Br J Cancer. 2004;90:304–305
  35. Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother. 2006;7:1041–1053
  36. Gradishar WJ, Tjulandin S, Davidson N, et al. Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: Results of a Phase III trial. J Clin Oncol. 2005;23:7794–7803
  37. Muggia FM, Liu PY, Alberts DS, et al. Intraperitoneal mitoxantrone or floxuridine: Effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy – A randomized phase II study by the Southwest Oncology Group. Gynecol Oncol. 1996;61:395–402
  38. Muggia FM, Jeffers S, Muderspach L, et al. Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin). Gynecol Oncol. 1997;66:290–294
  39. Newman E, Potmesil M, Ryan T, et al. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: A phase II study. Semin Oncol. 2005;32:S97–S100
  40. Newman E, Chang RY, Potmesil M, et al. Postoperative intraperitoneal (IP) 5′-fluoro-2′-deoxyurine (FUDR) added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Proc Am Soc Clin Oncol. 2005;23:348s;(abstr 4163)
  41. Robertson MD, Malpass TW, McGonigle KD, et al. Phase II study of intraperitoneal topotecan as consolidation chemotherapy in ovarian cancer. Proc Am Soc Clin Oncol. 2004;22:5077;(abstr)
  42. Plaxe SC, Christen RD, O’Quigley J, et al. Phase I and pharmacokinetic study of intraperitoneal topotecan. Invest New Drugs. 1998;16:147–152
  43. Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol. 2003;90:S8–S15
  44. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996;56:3087–3090
  45. Viens P, Petit T, Yovine A, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol. 2006;17:429–436
  46. In:  Kelland LR,  Farrell NP editor. Part III: Clinical Antitumor Activity and Toxicology of Platinum Drugs. In: Platinum-Based Drugs in Cancer Therapy. Totowa, NJ: Human Press; 2000;p. 171–299
  47. Du Bois A, Pfisterer J. Future options for first-line therapy of advanced ovarian cancer. Int J Gynecol Cancer. 2005;15:42–50
  48. Hofstra LS, Bos AM, de Vries EG, et al. A phase I and pharmacokinetic study of intraperitoneal topotecan. Br J Cancer. 2001;85:1627–1633
  49. Sood AK, Lush R, Geisler JP, et al. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: Results of a phase II trial. Clin Cancer Res. 2004;10:6080–6085
  50. Bos AM, De Vos FY, de Vries EG, et al. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. Eur J Cancer. 2005;41:539–548
  51. Andreopoulou E, Chen T, Liebes L, et al. Topotecan (Topo) +/− cisplatin for intraperitoneal (IP) consolidation after platinum-based induction of epithelial ovarian cancer (EOC). Ann Oncol. 2006;17(suppl 9):175;(abstr 550)
  52. Fukuoka M, Masuda N. Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol. 1994;34:105–111
  53. Choi SH, Tsuchida Y, Yang HW, et al. Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice. Cancer Lett. 1998;124:15–21
  54. Sugiyama T, Yakushiji M, Nishida T, et al. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett. 1998;128:211–218
  55. Adachi S, Ogasawara T, Yamasaki N, et al. A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn J Clin Oncol. 1999;29:434–437
  56. Koczywas M, Morgan R, Synold T, et al. Phase I trial of IP gemcitabine in the treatment of peritoneal carcinomatosis: Toxicity and pharmacokinetics. Proc Am Soc Clin Oncol. 2002;21:81s;(abstr)
  57. Sabbatini P, Aghajanian C, Leitao M, et al. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: Results of a phase I/II trial. Clin Cancer Res. 2004;10:2962–2967
  58. Gamblin TC, Egorin MJ, Zuhowski EG, et al. Intraperitoneal gemcitabine therapy for advanced adenocarcinoma of the pancreas. Ann Surg Oncol. 2004;11(suppl 2):S55;(abstr)
  59. Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267–272
  60. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first line chemotherapy in metastatic colorectal cancer. J Clin Oncol. 1998;16:2739–2744
  61. Giachetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomoduled fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–147
  62. Sugarbaker PH, Cunliffe W, Belliveau JF, et al. Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treat. 1988;1:66–79
  63. Elias D, Raynard B, Bonnay M, et al. Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studies. Eur J Surg Oncol. 2006;32:607–613
  64. Teicher BA, Chen C, Shih C, et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res. 2000;6:1016–1023
  65. Berek JS, Markman M, Blessing JA, et al. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study. Gynecol Oncol. 1999;74:48–52
  66. Berek JS, Markman M, Stonebraker B, et al. Intraperitoneal interferon-alpha in residual ovarian carcinoma: A phase II gynecologic oncology group study. Gynecol Oncol. 1999;75:10–14
  67. Alberts DS, Hannigan EV, Liu PY, et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. Gynecol Oncol. 2006;100:133–138
  68. Moore DH, Valea F, Walton LA, et al. A phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: A Gynecologic Oncology Group pilot study. Gynecol Oncol. 1995;59:267–272
  69. Barakat RR, Sabbatini P, Bhaskaran D, et al. Intraperitoneal chemotherapy for ovarian carcinoma: Results of long term follow-up. J Clin Oncol. 2002;20:694–698
  70. Ottow RT, Steller EP, Sugarbaker PH, et al. Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models. Cell Immunol. 1987;104:366–376
  71. Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: Twenty-four-hour versus 7-day infusion. J Clin Oncol. 1997;15:3399–3407
  72. Madhusudan S, Tamir A, Bates N, et al. A multicenter phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res. 2004;10:2986–2996
  73. Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial. J Clin Oncol. 2001;19:4183–4184
  74. Prat J, Ribé A, Gallardo A, et al. Hereditary ovarian cancer. Hum Pathol. 2005;36:861–870
  75. Rose SL, Buller RE. The role of p53 mutation in BRCA1-associated ovarian cancer. Minerva Ginecol. 2002;54:201–209
  76. Goodheart MJ, Ritchie JM, Rose SL, et al. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res. 2005;11:3733–3742
  77. Dinulescu DM, Ince TA, Quade BJ, et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005;11:63–70
  78. Howell SB, Pfeiffle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97:845–851
  79. Howell SB, Zimm S, Markman M, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol. 1987;5:1607–1612
  80. King ME, Pfeiffle CE, Howell SB. Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma. J Clin Oncol. 1984;2:662–669

 This activity is supported by an unrestricted educational grant from MedImmune Oncology, Inc., a subsidiary of MedImmune, Inc.

PII: S0093-7754(06)00428-3

doi: 10.1053/j.seminoncol.2006.11.006

Seminars in Oncology
Volume 33 , Pages 18-24 , December 2006

Article Tools